This guidance applies to analytical procedures used for release and stability testing of commercial drug substances and products, hereafter referred to as products. The guidance can also be applied to other analytical procedures used as part of the control strategy (ICH guidance for industry Q10 Pharmaceutical Quality System (April 2009)) following a riskbased approach.
The scientific principles described in this guidance can be applied in a phase-appropriate manner to analytical procedures used during clinical development.